New Resource Educates about Therapies for DVTA new resource for patients with deep vein thrombosis aims to educate about interventional therapies.
Anticoagulants Linked to Lower Dementia RiskOral anticoagulants are associated with a significant reduction in dementia risk for atrial fibrillation patients.
Newer Anticoagulants May Reduce Intraocular BleedingThe risk of intraocular bleeding was reduced by one-fifth when using newer anticoagulants versus warfarin in a new study.
Using NOACs Reduces Bleeding RisksDual antithrombotic therapy using dabigatran significantly reduces risk of bleeding compared to triple therapy using warfarin.
Rivaroxaban Shown to Cut Risk of Cardiovascular EventsRivaroxaban (Xarelto, Janssen/ Bayer) has been found to significantly reduce the risk of strokes and heart attacks in patients with artery disease.
Patient and Physician Education Boosts Anticoagulant Adherence RatesEducation about anticoagulants helped boost adherence rates and led to a small decrease in stroke risk.
Anticoagulation in AF: More than just a risk score?At the 2015 AHA Fall Conference, Daniel E. Singer, MD, spoke about the current shortcomings of atrial fibrillation guidelines that use the CHADS-VASc score.
How to identify AF patients at low stroke riskIn a presentation at the 2015 AHA Fall Conference, Daniel E. Singer, MD, spoke about identifying patients with an increased bleeding risk with the long-term use of oral anticoagulants and whether or not there is a benefit in those cases.
Major safety concerns with top-selling prescription drugsMajor safety concerns exist for many top-selling prescription drugs including benzodiazepines/prescription sleep aids, anticoagulants, cholesterol-lowering statins, oxycodone and hydrocodone, and stimulants. The following provides an overview of these classes and issues.
Edoxaban: An oral inhibitor of factor Xa